Pipeline
Focusing on Solid Tumors
Novel platform technology enabling rapid expansion to broad indications and patient populations
Proprietary targeted therapeutics aimed at unmet medical need and with global rights
Multiple differentiated ADC assets with best in class or first in class potential
